Business
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts. Abstracts accepted for poster presentation Title: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologiesPoster #: B018Presenter: Matthew R. Tonini, Senior Scientist, Tango TherapeuticsDate and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m. Title: Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer modelsPoster #: B098Presenter: Steven Lombardo, Scientist, Tango TherapeuticsDate and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m. Title: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repairPoster #: B054Presenter: Antoine Simoneau, Senior Scientist, Tango TherapeuticsDate and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m. Title: Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitorPoster #: B139Presenter: Maxwell Sherman, Ph.D., Co-Founder and CSO, Serinus BiosciencesDate and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m. Title: Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screensPoster #: C048Presenter: Silvia Fenoglio, Principal Scientist, Tango TherapeuticsDate and Time: Saturday, October 14; 12:30 p.m. – 4:00 p.m. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology ta...